Vimta Labs Limited

VIMTALABSNSE

Market snapshot · 2026-08-10 22:54 UTC

₹645.65

₹-5.60 (-0.86%)

MARKET CAP

₹2.89K Cr

STOCK P/E

36.2x

52W HIGH

₹902.65

52W LOW

₹376.05

BOOK VALUE

₹102.28

EPS

₹17.84

ROE

—

SECTOR

Health Care

DEBT/EQUITY

0.73

VOLUME

1.13L

P/B RATIO

6.31x

PEG RATIO

—

Sector

Health Care

Themes

Labs & Life Sciences Services

Dividend

AI Summary

✦ Clartha

Price Forecast

Current

₹645.65

High Target

—

Median Target

—

Low Target

—

Price history (1Y)

Analyst target range

Probabilistic Range

Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.

Time horizonRange (₹)Probability

3M₹455.55 - ₹875.9580%

6M₹389.26 - ₹981.2980%

12M₹307.67 - ₹1,13880%

Realized vol: +51.0% · Drift: +4.3%

Revenue Forecast

₹ Cr

Dec '25Current₹99.0

Sep 2026 ETrend estimate range

High₹134.8Base₹124.8Low₹114.8

PastCurrentTrend estimate: Low / Base / High

EPS Forecast

₹ / share

Dec '25Current₹3.96

Sep 2026 ETrend estimate range

High₹3.50Base₹3.12Low₹2.75

PastCurrentTrend estimate: Low / Base / High

Analyst price target unavailable from FMP/yfinance. Analyst pillar unavailable from FMP/yfinance.

Market Intelligence

Multi-factor synthesis of 5 key dimensions

Overall Outlook

Mixed

37%

Analyst Consensus

Unavailable

Analyst coverage unavailable

Mean upsideNot available

Fundamentals

Moderate

Fundamentals institutional score is 44 using growth durability 44.5.

Valuation

Premium valuation

Valuation institutional score is 2 using relative multiple z-scores where peer dispersion is available.

Analyst Consensus

Unavailable

No usable analyst target or recommendation data was available.

Technical Structure

Mixed Momentum

Technicals institutional score is 52 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.

Market Sentiment

Neutral backdrop

Recent news flow is balanced or not decisive enough to tilt the tape. Based on 1 recent ticker-linked news items.

Signal Summary

Market intelligence remains Mixed. Available evidence provides partial support, while fundamentals and valuation remain considerations.

Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.

Fundamentals ModerateValuation Premium valuationTechnical Structure Mixed MomentumMarket Sentiment Neutral backdrop

Key Data Points

Mean Target PriceUnavailable

Mean UpsideNot available

Technical Score53%

Fundamental Score45%

Data CoverageMedium

Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.

Valuation Metrics

Trading 49.2% above historical median. Valuation is stable — currently in the strongly overvalued zone (z-score: +1.46). Confidence: 61%.

Forward Valuation Outlook

Forward outlook is unavailable because live next-12-month estimate data is not available for this ticker right now.

P/E

5Y Average

18.41

Current

36.51

Overvalued

29.34

Undervalued

14.49

EV/EBITDA

5Y Average

9.76

Current

19.19

Overvalued

13.42

Undervalued

5.72

P/S

5Y Average

3.48

Current

6.85

Overvalued

4.79

Undervalued

2.04

Peers & Comparison

Sector: Health Care · Theme: Labs & Life Sciences Services

Labs & Life Sciences Services Peers1 peer

Avg P/E: 42.7x

Company	Rev. Growth	Margin	P/E	vs Avg	52W Perf.
AARTI PHARMALABS LIMITED AARTIPHARMLabs & Life Sciences Services	+38.7%	10.4%	42.7x Fair	0% vs avg	-20.2%

WHY THESE PEERS

VIMTA LABS LIMITED trades at a discount (36.2x vs peer avg 42.7x), suggesting potential undervaluation relative to the Labs & Life Sciences Services cohort. Peers include AARTI PHARMALABS LIMITED — selected based on business model, industry classification, market cap similarity, and business theme alignment.

Financials

Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.

Latest revenue

₹99 CrDec 2025

Latest net profit

₹20 CrDec 2025

Latest EPS

₹3.96Dec 2025

Net margin

23.6%Dec 2025

Performance

Bars show revenue and net profit. The line shows net margin.

Rs crore + margin %

Revenue
Net income
Net margin %

Earnings

Revenue is shown in crores. EPS is rupees per share.

Rs crore + Rs/share

Revenue
EPS

Revenue to profit conversion

Bridge from operating numbers to profit for the latest reported period.

Rs crore

Latest reported period: Dec 2025

Debt level and coverage

Debt, cash and free cash flow compared on the same crore scale.

Rs crore

Annual view

Debt
Free cash flow
Cash & equivalents

Results

Metric	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Sales	80.8	82.19	64.39	80.1	72.73	73.32	83.14	89.92	94.44	97.56	102	98.63
Expenses	57.24	58.35	47.57	59.22	46.81	48.31	54.19	56.84	61.4	63.88	67.63	64.39
Operating Profit	15.56	15.39	8.22	12.24	18.08	17.09	20.73	23.27	23.83	23.82	23.98	23.32
OPM %	19.26%	18.72%	12.77%	15.28%	24.86%	23.31%	24.93%	25.88%	25.23%	24.42%	23.54%	23.64%
Other Income	0.67	0.59	2.04	0.89	0.38	0.69	0.68	1.23	1.64	1.75	2.66	1.83
Interest	0.25	0.44	0.61	0.53	0.53	0.47	0.41	0.58	0.44	0.32	0.37	0.16
Depreciation	8	8.45	8.6	8.64	7.84	7.92	8.22	9.81	9.21	9.86	10.24	10.92
Profit before tax	15.98	15.54	9.65	12.6	17.93	17.31	21	23.92	25.03	25.25	26.27	24.99
Tax %	23.34%	25.16%	16.27%	24.92%	21.25%	23.4%	22.1%	27.59%	26.93%	25.19%	24.17%	21.89%
Net Profit	12.25	11.63	8.08	9.46	14.12	13.26	16.36	17.32	18.29	18.89	19.92	19.52
EPS in Rs	5.54	5.25	3.47	4.26	6.31	5.98	6.58	7.86	4.11	4.25	4.46	3.96

All values in Rs. Crore unless otherwise stated. Source: CMIE Prowess, Quarterly Interim Standalone.

Shareholding Pattern

Holder	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Promoters	36.70%	36.67%	35.99%	35.90%	35.85%
FII	3.66%	3.49%	4.33%	4.59%	4.89%
DII	1.43%	1.42%	0.87%	0.11%	0.13%
Public	25.17%	24.01%	24.62%	25.12%	25.01%
Others	33.04%	34.41%	34.19%	34.28%	34.12%

Mar 2026

Promoters

FII

DII

Public

Others